Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) and Immix Biopharma (NASDAQ:IMMX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Valuation and Earnings
This table compares Syros Pharmaceuticals and Immix Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syros Pharmaceuticals | $9.94 million | 5.29 | -$164.57 million | ($4.30) | -0.46 |
| Immix Biopharma | N/A | N/A | -$15.43 million | ($0.93) | -1.85 |
Immix Biopharma has lower revenue, but higher earnings than Syros Pharmaceuticals. Immix Biopharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syros Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Immix Biopharma | 0 | 0 | 1 | 0 | 3.00 |
Syros Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 155.10%. Immix Biopharma has a consensus price target of $7.00, suggesting a potential upside of 306.98%. Given Immix Biopharma’s higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Syros Pharmaceuticals.
Risk and Volatility
Syros Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500.
Institutional and Insider Ownership
91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 55.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Syros Pharmaceuticals and Immix Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syros Pharmaceuticals | N/A | -850.20% | -94.06% |
| Immix Biopharma | N/A | -87.09% | -72.07% |
Summary
Immix Biopharma beats Syros Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
